EyeBio CEO David Guyer (L) and CSO Anthony Adamis

Eye­Bio dou­bles the size of its Se­ries A as an­ti-VEGF vet­er­ans seek new ways of treat­ing reti­nal dis­eases

Reti­nal dis­ease biotech Eye­Bio has dou­bled the size of its ini­tial Se­ries A raise from Feb­ru­ary 2022. With an­oth­er $65 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.